TMEM163

Across TCGA pan-cancer cohorts, TMEM163 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TMEM163 data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher TMEM163 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TMEM163 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

LSCC, LUAD, and PDAC are the cancer types where TMEM163 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	All	0.938	0.827	.004	7	view →
LUAD	DFS	Median	III,IV	1.000	0.498	.017	6	view →
PDAC	DFS	Quartile	II,III,IV	0.905	0.533	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TMEM163–LSCC (OS)

Open the LSCC breakdown →